145 related articles for article (PubMed ID: 37042235)
1. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
Bronstein Y; Levi S; Herishanu Y
Br J Haematol; 2023 Jun; 201(6):1125-1128. PubMed ID: 37042235
[TBL] [Abstract][Full Text] [Related]
2. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
3. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Niemann CU; da Cunha-Bang C; Helleberg M; Ostrowski SR; Brieghel C
Blood; 2022 Aug; 140(5):445-450. PubMed ID: 35588468
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants.
Lee JE; Hwang M; Kim YH; Chung MJ; Jeong WG; Sim BH; Jeong YJ
Radiology; 2023 Jul; 308(1):e230653. PubMed ID: 37462497
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Viruses; 2023 May; 15(6):. PubMed ID: 37376600
[TBL] [Abstract][Full Text] [Related]
6. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Passerini M; Ratishvili T; Monroe JM; Temesgen Z; Witzig TE; Kay NE; Kennedy RB; Parikh SA
Leuk Lymphoma; 2023 Apr; 64(4):874-883. PubMed ID: 36908110
[TBL] [Abstract][Full Text] [Related]
7. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
8. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
Feikin DR; Higdon MM; Andrews N; Collie S; Deloria Knoll M; Kwong JC; Link-Gelles R; Pilishvili T; Patel MK
Vaccine; 2023 Mar; 41(14):2329-2338. PubMed ID: 36797097
[TBL] [Abstract][Full Text] [Related]
9. Invalidity of JRS atypical pneumonia prediction score in Omicron variant of COVID-19 pneumonia.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Respir Investig; 2024 May; 62(3):384-387. PubMed ID: 38452443
[TBL] [Abstract][Full Text] [Related]
10. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
Morris CP; Eldesouki RE; Sachithanandham J; Fall A; Norton JM; Abdullah O; Gallagher N; Li M; Pekosz A; Klein EY; Mostafa HH
Clin Infect Dis; 2023 Apr; 76(7):1276-1284. PubMed ID: 36366857
[TBL] [Abstract][Full Text] [Related]
11. EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19.
Esmaeilzadeh A; Ebrahimi F; Jahani Maleki A; Siahmansouri A
Infection; 2024 Apr; 52(2):337-343. PubMed ID: 38170417
[TBL] [Abstract][Full Text] [Related]
12. Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study.
Li J; Zhang Q; Xu C; Zhang Y; Lu Y; Ai M; Tan X
BMC Gastroenterol; 2023 Aug; 23(1):271. PubMed ID: 37553605
[TBL] [Abstract][Full Text] [Related]
13. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
[TBL] [Abstract][Full Text] [Related]
14. Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.
Sridhara S; Gungor AB; Erol HK; Al-Obaidi M; Zangeneh TT; Bedrick EJ; Ariyamuthu VK; Shetty A; Qannus AA; Mendoza K; Murugapandian S; Gupta G; Tanriover B
PLoS One; 2023; 18(4):e0279326. PubMed ID: 37115780
[TBL] [Abstract][Full Text] [Related]
15. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada.
Russell SL; Klaver BRA; Harrigan SP; Kamelian K; Tyson J; Hoang L; Taylor M; Sander B; Mishra S; Prystajecky N; Janjua NZ; Zlosnik JEA; Sbihi H
J Med Virol; 2023 Jan; 95(1):e28423. PubMed ID: 36546412
[TBL] [Abstract][Full Text] [Related]
16. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
[TBL] [Abstract][Full Text] [Related]
17. Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau.
Xu C; Wang J; Yu L; Sui X; Wu Q
Front Public Health; 2022; 10():1029171. PubMed ID: 36703829
[TBL] [Abstract][Full Text] [Related]
18. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
19. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
Nazmunnahar ; Ahmed I; Islam MR
Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
[TBL] [Abstract][Full Text] [Related]
20. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
